Chemours Co (NYSE:CC) has been given an average recommendation of “Buy” by the fourteen brokerages that are covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $59.50.
CC has been the topic of several recent analyst reports. Citigroup reduced their target price on Chemours from $68.00 to $66.00 and set a “buy” rating on the stock in a research report on Tuesday. TheStreet upgraded Chemours from a “c+” rating to a “b-” rating in a research report on Monday, April 2nd. ValuEngine downgraded Chemours from a “buy” rating to a “hold” rating in a research report on Monday, April 2nd. BMO Capital Markets initiated coverage on Chemours in a research report on Tuesday, March 27th. They set an “outperform” rating and a $68.00 target price on the stock. Finally, Zacks Investment Research upgraded Chemours from a “hold” rating to a “strong-buy” rating and set a $58.00 target price on the stock in a research report on Wednesday, February 21st.
In other news, VP Mark Newman sold 29,381 shares of the firm’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $49.19, for a total value of $1,445,251.39. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Paul Kirsch sold 13,770 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $50.01, for a total value of $688,637.70. Following the completion of the transaction, the insider now owns 63,093 shares in the company, valued at $3,155,280.93. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Strs Ohio purchased a new position in shares of Chemours in the 4th quarter worth about $116,000. Clearbridge LLC grew its stake in shares of Chemours by 93.6% in the fourth quarter. Clearbridge LLC now owns 2,689 shares of the specialty chemicals company’s stock valued at $135,000 after buying an additional 1,300 shares in the last quarter. First Allied Advisory Services Inc. acquired a new stake in shares of Chemours in the third quarter valued at about $202,000. First Republic Investment Management Inc. acquired a new stake in shares of Chemours in the third quarter valued at about $203,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of Chemours in the fourth quarter valued at about $203,000. Institutional investors own 77.78% of the company’s stock.
Shares of NYSE:CC traded up $1.85 on Thursday, hitting $50.58. The company had a trading volume of 407,921 shares, compared to its average volume of 1,854,149. The company has a quick ratio of 1.55, a current ratio of 2.12 and a debt-to-equity ratio of 4.74. Chemours has a 52-week low of $34.70 and a 52-week high of $58.08. The company has a market capitalization of $8,885.27, a P/E ratio of 13.26, a P/E/G ratio of 0.58 and a beta of 2.94.
Chemours (NYSE:CC) last issued its quarterly earnings data on Wednesday, February 14th. The specialty chemicals company reported $1.19 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.24. Chemours had a return on equity of 115.54% and a net margin of 12.06%. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.55 billion. During the same period in the prior year, the business earned $0.08 earnings per share. The business’s revenue was up 19.1% on a year-over-year basis. sell-side analysts anticipate that Chemours will post 5.37 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/10/chemours-co-cc-receives-average-recommendation-of-buy-from-analysts.html.
Chemours Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.